Evidence map›Paper›PMID 26805845›Full record

ReviewSensors (Basel, Switzerland)2016

Graphene: The Missing Piece for Cancer Diagnosis?

Sandra M A Cruz, André F Girão, Gil Gonçalves, Paula A A P Marques

Abstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sandra M A CruzCoimbra Chemistry Center, Department of Chemistry, University of Coimbra, Coimbra 3004-535, Portugal. xcruz@ci.uc.pt.
André F GirãoNanoengineering Research Group, TEMA, Department of Mechanical Engineering, University of Aveiro, Aveiro 3810-193, Portugal. andrefgirao@ua.pt.
Gil GonçalvesNanoengineering Research Group, TEMA, Department of Mechanical Engineering, University of Aveiro, Aveiro 3810-193, Portugal. ggoncalves@ua.pt.
Paula A A P MarquesNanoengineering Research Group, TEMA, Department of Mechanical Engineering, University of Aveiro, Aveiro 3810-193, Portugal. paulam@ua.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper reviews recent advances in graphene-based biosensors development in order to obtain smaller and more portable devices with better performance for earlier cancer detection. In fact, the potential of Graphene for sensitive detection and chemical/biological free-label applications results from its exceptional physicochemical properties such as high electrical and thermal conductivity, aspect-ratio, optical transparency and remarkable mechanical and chemical stability. Herein we start by providing a general overview of the types of graphene and its derivatives, briefly describing the synthesis procedure and main properties. It follows the reference to different routes to engineer the graphene surface for sensing applications with organic biomolecules and nanoparticles for the development of advanced biosensing platforms able to detect/quantify the characteristic cancer biomolecules in biological fluids or overexpressed on cancerous cells surface with elevated sensitivity, selectivity and stability. We then describe the application of graphene in optical imaging methods such as photoluminescence and Raman imaging, electrochemical sensors for enzymatic biosensing, DNA sensing, and immunosensing. The bioquantification of cancer biomarkers and cells is finally discussed, particularly electrochemical methods such as voltammetry and amperometry which are generally adopted transducing techniques for the development of graphene based sensors for biosensing due to their simplicity, high sensitivity and low-cost. To close, we discuss the major challenges that graphene based biosensors must overcome in order to reach the necessary standards for the early detection of cancer biomarkers by providing reliable information about the patient disease stage.

Indexed as

Biosensing TechniquesOptical ImagingBiomarkers, TumorGraphiteHumansNeoplasmsBiomarkers, TumorGraphitebiosensorscancer biomarkerscancer cellsgraphene

Identifiers

PMID26805845
PMCPMC4732170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.